PRKN and breast cancer: Our data suggest that mitochondrial metabolism can be exploited by targeting the DYNLT1-Parkin-VDAC1 axis to further improve the ability of metabolic inhibitors to suppress breast cancers with limited treatment options, such as TNBC, in the future.